Intraperitoneal radiolabeled OC 125 in patients with advanced ovarian cancer

N J Finkler, Neil J. Finkler, M G Muto, Michael G. Muto, A I Kassis, Amin I. Kassis, K Weadock, Kevin Weadock, Sabah S. Tumeh, S S Tumeh, V R Zurawski, Vincent R. Zurawski, R C Knapp, Robert C. Knapp
Gynecologic oncology · 1989 · doi:10.1016/0090-8258(89)90169-8 · PMID:2767526
other OA: closed public-domain-us
View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

Intraperitoneal iodine-131-labeled OC 125 was safely administered to patients with advanced ovarian cancer, with rare side effects and no dose-limiting toxicities observed.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Twenty patients with recurrent or persistent epithelial ovarian cancer failing conventional therapies were treated with a single intraperitoneal injection of iodine-131-labeled OC 125 monoclonal antibody. Rare acute side effects were nausea and mild diarrhea. At doses up to 120 mCi of iodine-131, median white blood cell and platelet count nadirs were 3.6k/microliters and 187k/microliters, respectively. Two patients acquired thyroid toxicities despite thyroid blockage with "cold" iodine. One patient had transient TSH elevation while remaining clinically euthyroid, and 1 patient developed activation of a thyroid nodule and clinical hyperthyroidism. Dose-limiting toxicity has not yet been observed. Twelve of 20 patients are alive 3 to 17 months following therapy. Tumor progression was noted in the majority of patients, although 3 patients had documented decreases in tumor burden of short duration. We conclude that, at the doses examined, iodine-131 OC 125 can be safely administered intraperitoneally.

My notes (saved in your browser only)

Condition tags

mesh:D004715

MeSH descriptors

Antibodies, Monoclonal Iodine Radioisotopes Ovarian Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma Adenocarcinoma Adult Aged Animals Antibodies, Monoclonal Antibodies, Monoclonal Carcinoma, Papillary Carcinoma, Papillary Carcinoma, Papillary Carcinoma, Papillary Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (11)

Source provenance

crossref
last seen: 2026-05-16T01:00:16.605182+00:00
europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine